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Abstract
Constipation is common in advanced cancer. Despite this, clinicians’ understanding of the underlying changes
affecting the colon and the rest of the gastrointestinal tract are limited. Two case histories are used to illustrate
the problems encountered when the current approaches to diagnosing and managing altered bowel habits are
unsuccessful. An alternative paradigm in which to consider the problems of constipation encountered by some
people with advanced cancer is proposed.
Introduction
Constipation is common and often distressing in ad-vanced cancer. Similar to ‘‘depression,’’ which has both
common usage and a specific scientific definition, the term
‘‘constipation’’ is confusingly used to both describe a symp-
tom and a diagnosis. This problem is exacerbated by the
disparity between patients’ and health professionals’ opin-
ions. Patients tend to report constipation as any of several
changes in their bowel movements. This contrasts with clini-
cians who usually describe constipation in terms of the stool
appearance and frequency.
In the wider community, two constipation subtypes are
recognized: functional or primary and secondary.1 Functional
constipation affects up to nearly 30% of the total population.2,3
Unlike secondary constipation, functional constipation has a
consensus and diagnostic definition, the Rome Criteria4 (Table 1).
In contrast, no agreed standards for definition and diagnosis
of secondary constipation exist. Within palliative care, con-
stipation is usually considered a result of multiple insults.
When adopting a palliative approach to symptoms, the
initial, most logical step is to identify the dominant underly-
ing pathophysiology then correcting or modifying this if
possible. Even for people with advanced disease, this includes
appropriate investigations when tolerable. Approaching
constipation in this framework is handicapped by the sparce
evidence that objectively identifies risk factors and underlying
mechanisms. As a result, current approaches to investigating
and managing constipation are poorly evidence based. These
problems are highlighted here.
Case Histories
Case 1
A 60-year-old woman with metastatic peritoneal sarcoma
presents with 7 days of poorly localized cramping abdominal
pain, nausea, bloating, and infrequent passage of flatus and
stool. These were new problems and previously she had
functioning independently and not requiring any regular
medications. In particular, she did not have a past history of
constipation. A bowel obstruction was suspected. Physical
examination revealed mild, diffuse abdominal tenderness,
audible soft bowel sounds, and a collapsed empty rectum.
Investigations did not show hypercalcaemia or other abnor-
malities. On plain radiograph, the bowel was not dilated,
there were no fluid levels but fecal material was visible in the
entire ascending colon.
On this basis, intestinal obstruction was excluded and she
was diagnosed with constipation. She was given sodium
phosphate stat orally and rectally. Regular oral polyethylene
glycol with electrolytes (PEGþE) three times per day was
commenced.
She did not pass stool leading to a second radiograph 24
hours later, which was unchanged. Oral PEGþE was con-
tinued, with little response, for 3 more days, after which she
started passing small amounts of brown liquid.
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Case 2
A 55-year-old independently functioning woman with
stage IV ovarian cancer presented 2 weeks after completing
her first course of chemotherapy with a 2-day history of
constant lower abdominal pain, nausea, vomiting, and re-
duced frequency of passing flatus and bowel motions. She
also was not receiving regular opioid or anticholinergic
medications and reported no past history of constipation. At
presentation, her abdomen was mildly distended and tender,
without guarding. Bowel sounds were soft to auscultation
and her rectum was empty.
Her investigations were unremarkable. Abdominal radio-
graph excluded bowel obstruction in the absence of air=fluid
levels, but fecal material was visible in the descending colon.
She was diagnosed with constipation and commenced on
twice-daily PEGþE and lactulose 20 mL, with daily Micro-
lax enemas ( Johnson & Johnson Pacific Pty, New South
Wales, Australia). There was little result and she remained
nauseated, finding it difficult to tolerate anything orally.
Another radiograph 48 hours later only showed fecal material
in the colon. A third radiograph 4 days showed some air-fluid
levels without dilatation.
Discussion
These scenarios are commonplace but highlight how lim-
ited current understanding is of the problems that affect the
bowel in advanced cancer and how this is best diagnosed and
managed.
Likely causes of constipation
Based on the prevalence of functional constipation, up to
30% of people will come to their life-limiting illness with this
problem, suggesting that this may be either the predominant
cause of their constipation, changed bowel habits, problems
or at least a significant contributing factor potentially exac-
erbated by systemic or local factors associated with their ill-
ness. Other lists of factors that potentially contribute to
constipation are readily available in palliative care.5 The evi-
dence that underlies such lists are variable. Opioid analgesia
is perceived as one of the most common causes, and as a
result, the most attributed cause of constipation in advanced
cancer. This was not so in neither case, nor were other con-
tributing medications such as those with anticholinergic ef-
fects use. Some contributing factors include altered mobility
and oral intake and sites of disease. To date, the evidence
supporting performance status is inconclusive. Decreased
oral intake has better evidence in other parts of medicine than
in palliative care. Both cases had peritoneal involvement.
Anecdotally, such sites of disease in gynecologic cancers are
widely accepted as cause of disturbed gastrointestinal motil-
ity. The literature describes changes in motility of people with
upper gastrointestinal stromal tumors, with reports suggest-
ing these malignancies arise from the Cajal cells of the
myenteric plexus.6 Peritoneal metastases from adenocarci-
noma of the bowel are suggested to exert increased intra-
abdominal pressure leading to gut wall oedema, a problem
that causes disturbed transit.7 Last, paraneoplastic effects on
the myenteric plexus or smooth muscle through the actions of
tumor-specific antibodies affect motility. Pararaneoplastic
intestinal pseudo-obstruction has been reported in small cell
lung cancer, thymoma, ovarian cancer, breast cancer, and
neuroblastomas secondary to circulating ANNA-1 antibodies.
Constipation alone is a very rare paraneoplastic phenomena.8
Plain radiographs to diagnose constipation?
In both cases, radiographs revealed fecal matter occupying
different colonic segments. There was no clinical or radiologic
evidence of bowel obstruction, rectal fecal impaction, para-
lytic ileus, or pseudo-obstruction at presentation. Plain ra-
diographs when reviewed by experienced clinicians are likely
to provide an accurate diagnosis of obstruction 66%–83% of
the time9 leading to diagnoses of ‘‘constipation’’ by exclusion.
Perhaps it is more accurate to conclude that only ‘‘bowel ob-
structions’’ were excluded.
The practice of diagnosing constipation with a plain ra-
diograph assumes that the appearance of stool in the colon at
one time point provides a reproducible marker of the passage
of stool through the colon. Within a functionally constipated
adult population, systematically reviewing the role of plain
radiographs to diagnosis constipation led to the conclusion
that the evidence is insufficient to recommend this.10 Other
observations refute single plain radiographs to diagnose
constipation. A convenience sample of 100 volunteers from a
constipation clinic failed to confirm significant correlations
between the degrees of fecal loading on plain radiograph, self-
reported constipation symptoms, and objective measures of
colon transit times.11 There were wide ranges of interobserver
variability with exact agreement in 18% of reports and com-
plete disagreement noted in 10% of reports. Last, retrospective
examination of abdominal radiographs previously taken to
diagnose constipation in 144 palliative care inpatients failed to
identify a correlation between a fecal loading score and a
clinical diagnosis of constipation.12
The radiograph offers little more than a ‘‘snapshot’’ of the
colon at that time and it is not possible to conclude if the
appearance of a single radiograph is a normal variant for this
person or if the presence of colonic matter is pathologic, re-
sulting either from impaired gut function due to the bolus of
the fecal matter itself or if the fecal matter is accumulating as a
result of another more complex pathology.
Table 1. Rome Criteria for Functional Constipation
Diagnostic criteria for functional constipation with criteria
fulfilled for the last 3 months and symptom onset at least
6 months before diagnosis
1. Must include two or more of the following:
a. Straining during at least 25% of defecations
b. Lumpy or hard stools in at least 25% of defecations
c. Sensation of incomplete evacuation following at least
25% of defecations
d. Sensation of anorectal obstruction or blockage during
at least 25% of defecations
e. Manual manoeuvres to facilitate for at least 25% of
defecations (e.g., digital evacuation, support of the
pelvic floor)
f. Fewer than three defecations per week
2. Loose stools rarely present without the use of laxatives
3. Insufficient criteria for IBS
IBS, irritable bowel syndrome.
See Longstretch et al., 2006.
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Lack of response to laxatives?
In both cases, responses to trials of laxatives was unsatis-
factory. According to the product information, the passage of
frequent liquid stool is to be within 30 minutes after admin-
istration of a single dose of sodium phosphate liquid.13 Rectal
administration of sodium phosphate liquid should result in
the passage of stool within 2 to 3 minutes.14 The onset of
laxative action of PEGþE depends upon the severity of the
severity of the constipation being treated but it is expected
that by the end of 3 days, up to 90% of people should have a
response.15 In contrast, despite the ongoing use of two to three
sachets per day for at least 5 days each, neither of the cases had
such a response. The recommended doses of lactulose for
constipation are 15 to 30 mL daily. At this dose, relief of
constipation should be expected in 24 to 48 hours,16 again a
response not witnessed in the case presented here. Lastly, a
response to a Microlax enema should occur within 30 min-
utes of administration.17 Although it could be argued that the
choices of laxatives were inappropriate and alternative com-
binations such as senna may have been more palatable for
these people, there are very limited data to support the
superiority of one agent over another in any palliative care
situation.18
In a functionally constipated population, failing to respond
to laxative trial would prompt other investigations to better
categorize the problem, either obstruction, slow transit or
pelvic floor dysfunction.19 Both cases excluded obstructions,
an imperative based on their symptoms. However subsequent
investigations may have been useful to better define what
changes actually underpinned their presentations. Colon
transit times may be simply and cheaply measured by com-
bining orally ingested radioopaque markers with plain
radiographs to calculate the transit hours.20 More costly ap-
proaches include scintigraphy or colonic manometry. Other
specialized, invasive tests are required for assessing pelvic
floor dysfunction, including balloon expulsion, anorectal
manometry, and defecography.3 This standard approach in
gastroenterology has not been explored in the constipation
advanced cancer, despite the prevalence and severity of the
problem.
Adverse effects of laxatives?
In this vacuum of understanding, questions are raised as to
whether there may be detrimental effects by treating the
people with laxatives when the undying problem is not
clearly defined. Despite the frequency with which people with
advanced cancer are prescribed laxatives, the data to describe
laxative’s adverse effects in this frail population are still
sparse18 and no identified studies report the use of laxatives in
people similar to those described in this paper and their
clinical outcomes. Some data are available from 388 very
unwell, intubated intensive care patients without paralytic
ileus or obstruction (mechanical, pseudo-obstruction) in
whom the use of placebo was compared to either lactulose or
polyethylene glycol to induce defecation.21 Higher incidences
of paralytic ileus and acute intestinal pseudo-obstruction oc-
curred in the lactulose-treated group (5 versus 1), but this not
a statistically significant difference. An increased incidence of
colonic distension was noted in lactulose group. This occurs
secondary to metabolism of lactulose by colonic bacteria into
short chain fatty acids with the byproducts of hydrogen,
methane, and carbon dioxide that accumulate when intestinal
passage is delayed. As these people were intubated, it is not
possible to explore how this was experienced. Whilst this
study was not of people with advanced cancer, it was of
people with impaired gut transit due to the identified risks of
opioid analgesia, gut oedema and immobility.22 Although
not mentioned, the incidence of functional constipation in the
whole community suggests that at least some of the partici-
pants must have some preexisting gut pathology.
Conclusion
It seems very logical to better explore the problem of con-
stipation in advanced cancer this by examining the paradigms
that already exist in gastroenterology. This would allow a
clearer and more objective understanding of how the passage
of gut contents in this patient group is affected. In turn, this
would begin a process to develop a system that allows clas-
sification and grading of the different scenarios. Ultimately,
the major goal is to develop a structure where interventions
can be tailored to the underlying problem.
There are challenges to this process including assessing
the impact of multiple confounding factors that may com-
plicate gut function in this group and the problems associated
with progressive frailty with advancing disease. However,
given the costs and burdens associated with constipation, it
seems more unethical not to consider evidence-based alter-
natives that could lead to improved comfort and quality of
life.
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